QualityStocks would like to highlight Premier Biomedical (OTCBB: BIEI), a medical development company specializing in breakthroughs for serious illnesses. The company has acquired exclusive licenses for patent-pending medications and medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, Alzheimer’s Disease, Blood Sepsis, Atherosclerosis, and Cancer. They have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials.
In the company’s news yesterday,
Premier Biomedical has announced successful advances in cancer-focused research. The company’s researchers have successfully killed a cancer tumor in a test tube by simply removing crucial molecular compounds that are necessary for the cancer’s development. They accomplished this by utilizing the Felder Doctrine, which states: “Physically remove the pathophysiologic basis of the disease.”
Currently used methods for treating cancer, like chemotherapy and many conventional cancer-fighting drugs, are able to target only one single antigen, which permits another antigen to survive the treatment and allows the cancer to progress. Additionally, these blockers or inhibitors are frequently accompanied by dangerous side effects for patients. Premier Biomedical’s focus is to aim for far greater efficiency through simultaneously mixing and matching multiple cancer target antigens. The company actually removes the disease’s pathophysiologic basis – targeting the precise cause of the disease and eliminating it without dangerous side effects.
Premier Biomedical’s researchers have specifically removed a particular cancer-related Interleukin from a heterogeneous mixture at a pictogram (trillionth of a gram) level of accuracy. This can potentially open the door to a methodology for eradicating cancer tissue without using any other medications and/or procedures, which are often accompanied by related side effects. Additional testing has resulted in the successful removal of additional critical cancer-related antigens that are important to the development, growth, and metastasis of cancer tissue. The focuses of these recent successes were leukemia and lymphoma cancers.
Premier Biomedical is a research-based company operating on the intent of discovering and developing medical treatments for humans – specifically targeting the treatment of Alzheimer’s disease, fibromyalgia, multiple sclerosis, traumatic brain injury, amyotrophic lateral sclerosis (ALS/Lou Gehrig’s Disease), blood sepsis and viremia, and cancer. The company has licensed the technology behind various provisional patents in the U.S. and a PCT Europe National Patent in the areas of cancer, sepsis, and MS. Premier was founded in 2010 and is headquartered in Florida, with offices in Pennsylvania.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
